Pharma and biotech | PA Consulting

Pharma and biotech companies are at the forefront of innovation and critical to improving health outcomes, globally. With a host of exciting advances in science and technology, and a renewed appetite to accelerate new treatments to market, we’re empowering companies to deliver preventative and curative care that meets patients where they are.

Pharma and biotech organisations have an opportunity to challenge orthodoxy, push technology boundaries and deliver a greater, more enduring impact across healthcare.

Is your organisation ready to deliver a greater step-change in patient care?

Working together

We partner with pharma and biotechs to determine the most effective strategies for developing, manufacturing, and commercialising drug products and digital health solutions.

Working at the intersection of technology, science, innovation, strategy, and healthcare, we help you navigate and chart the evolving research, development, manufacturing, supply chain and commercial landscapes to accelerate therapies to market and improve patient care.

Talk to us about

Clinical trial transformation

Build a new generation of clinical trials through end-to-end automation, AI, and the latest data privacy and security solutions.

Quality, regulatory, and compliance

Deliver on patient safety in a modern enterprise through risk-based design and digitisation of processes, benchmarking of cost, and optimisation of systems.

Supply chain

Shape future supply chains by integrating data to gain control over spend, reduce your climate impact, and deliver resilience.

Advanced manufacturing

Develop new manufacturing processes and intelligent assets to bring higher performance and agility.

Cell and gene therapy

Realise the promise of cell and gene therapies through advanced analytics, automation, manufacturing process development, technology strategy development, and innovative manufacturing technologies.

Digital trust

Create a secure and compliant data ecosystem, integrating cyber security, data privacy compliance programmes, third-party risk management, responsible AI, and data governance.

Drug delivery

Enable safe, effective, and intuitive delivery of therapies through connected devices, complex development programmes and user-centered designs.

Featured insight

Woman seated on row of chairs reading document

Report

Combination product QMS requirements for pharma companies entering the EU market

Our experts discuss the challenges and considerations for companies looking to enter the EU market with combination products.

Spotlight

Global Innovation and Technology Centre

Where we turn ideas into physical and digital reality.

Expert views

An industry-wide consensus on how to harmonise digital approaches in cell and gene therapy, would go a long way in removing key barriers to digital innovation and adoption.”

Gloria Lam Cell and gene therapy

Read the insight

Many life science companies are increasingly breaking down the silos they used to be comfortable with and establishing cross-functional teams that focus on unified and holistic solutions for healthcare professionals and patients.”

Johanne Rønnow Olsen Pharma

Read the insight

France, Italy, and the UK will be breeding grounds to collect the data but unless the frameworks there evolve to give a large percentage of the pricing benchmark, it will be an afterthought in most companies’ minds in terms of getting significant market share or revenue.”

Vignesh Ramesh Digital health

Read the insight

The future will require more digitally connected solutions, and this will facilitate more community and home-based healthcare systems with changing models of care which are ultimately more patient-centric.”

Hilary Thomas Healthcare and life sciences

Read the insight

It is important to have software updates which are easy for patients to install or are applied automatically. Device manufacturers need to offer a range of services to support products in-life, such as registration, device recalls, vulnerability reporting and vulnerability disclosure to regulators.”

Mayur Patel Life sciences

Read the insight